Clinical trials: Autologous Stem Cell Transplantation
Newly Diagnosed Multiple Myeloma, Multiple Myeloma
Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation
This Phase II hybrid decentralized trial will examine the effect of daratumumab-based quadruplet induction therapy administered at an attenuated schedule in subjects with newly diagnosed multiple myeloma (NDMM) who are eligible…
- Conditions
- Newly Diagnosed Multiple Myeloma, Multiple Myeloma, Autologous Stem Cell Transplantation
- Trial name
- NCT06348147
- Testing
- Daratumumab, Lenalidomide, Bortezomib
- Where
- United States
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Lymphoma, B-Cell, Autologous Stem Cell Transplantation
Clinical Study of CAR-T Cell Therapy Following ASCT for R/R B-cell Non-Hodgkin's Lymphoma
The study is designed to evaluate the efficacy and safety of chimeric antigen receptor T-cell therapy following autologous stem cell transplantation for relapsed/refractory B-cell Non-Hodgkin's lymphoma.
- Trial name
- NCT06381830
- Testing
- Apheresis, Autologous Stem Cell Transplantation, CAR-T Cell Therapy
- Where
- China
- Volunteers
- 8 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Ovarian Insufficiency, Autologous Hematopoietic Stem Cell Transplantation
Clinical Study on the Preservation of Ovarian Function Following Autologous Hematopoietic Stem Cell Transplantation Using Goserelin
This study is a prospective, multicenter, randomized controlled clinical trial planned to enroll 64 female hematologic patients aged 14 to 50 years scheduled for autologous hematopoietic stem cell transplantation (auto-HSCT).
- Trial name
- NCT07552493
- Testing
- Goserelin 3.6 MG
- Where
- 5 sites in China
- Volunteers
- 64 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, Autologous Haemopoietic Stem Cell Transplant
Nutrition OUtReach In Systems of Healthcare
Many children and adults receiving medical treatments have higher costs, which can make it harder for them to afford groceries. When someone can't afford enough food, and they do not receive proper nutrition it can make treatment…
- Conditions
- ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, Autologous Haemopoietic Stem Cell Transplant, CAR-T Cell Therapy, Food Insecurity
- Trial name
- NOURISH (NCT06802406)
- Testing
- Food Bags
- Where
- 4 sites in United States
- Volunteers
- 210 people
- Sponsor
- University of Kansas Medical Center
Systemic Sclerosis, Systemic Scleroses, Diffuse
Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis
HSCT has been implemented in (inter)national treatment guidelines for diffuse cutaneous systemic sclerosis (dcSSc) and is offered in clinical care and reimbursed by national health insurance in several European countries.
- Conditions
- Systemic Sclerosis, Systemic Scleroses, Diffuse, Scleroderma, Scleroderma, Diffuse
- Trial name
- UPSIDE (NCT04464434)
- Testing
- Upfront autologous HSCT
- Where
- 8 sites in Italy, Netherlands and 1 more
- Volunteers
- 60 people
- Sponsor
- UMC Utrecht
Hematologic Malignacy, Autologous Hematopoietic Stem Cell Transplantation
Exercise in Patients Undergoing Autologous Stem Cell Transplantation: A Randomized Controlled Trial
This interventional study assigns participants undergoing autologous hematopoietic stem cell transplantation to a supervised exercise program or usual care.
- Trial name
- NCT07458854
- Testing
- Exercise Program
- Where
- Turkey (Türkiye)
- Volunteers
- 15 people
- Sponsor
- TC Erciyes University
Delayed Platelet Engraftment, Neuroblastoma
Hetrombopag in Promoting Platelet Engraftment After Auto-HSCT in Children With Neuroblastoma
The goal of this clinical trial is to learn if hetrombopag promotes platelet engraftment in neuroblastoma children undergoing autologous hematopoietic stem cell transplantation.
- Conditions
- Delayed Platelet Engraftment, Neuroblastoma, Autologous Hematopoietic Stem Cell Transplantation
- Trial name
- NCT06818916
- Testing
- Hetrombopag
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Beijing Children's Hospital
Multiple Myeloma, Daratumumab
Daratumumab-containing Induction Effects on Stem Cells Mobilization, colLection and Engraftment in Newly Diagnosed Multiple MyelomA Patients.
Daratumumab is a human first-in-class monoclonal antibody that targets a cluster of differentiation (CD) 38, a cell surface protein that is overexpressed on multiple myeloma (MM) cells, showing significant activity in…
- Conditions
- Multiple Myeloma, Daratumumab, Autologous Stem Cell Transplantation, Leukapheresis
- Trial name
- DILEMMA (NCT05835726)
- Testing
- Daratumumab
- Where
- Italy
- Volunteers
- 188 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Autologous Stem Cell Transplantation, Allogeneic Stem Cell Transplantation
CIBMTR Research Database
The primary purpose of the Research Database is to have a comprehensive source of observational data that can be used to study HSC transplantation and cellular therapies.
- Conditions
- Autologous Stem Cell Transplantation, Allogeneic Stem Cell Transplantation, Solid Tumors, Blood Cancers
- Trial name
- NCT01166009
- Where
- 2 sites in United States
- Volunteers
- 99,999,999 people
- Sponsor
- Center for International Blood and Marrow Transplant Research
Multiple Myeloma, Autologous Stem Cell Transplantation
Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan
Patients who receive a chemotherapy called melphalan are at high risk of having nausea and vomiting. A medication called olanzapine has been shown to decrease nausea and vomiting after chemotherapy.
- Trial name
- FONDO-LOW (NCT06588413)
- Testing
- Olanzapine
- Where
- United States
- Volunteers
- 172 people
- Sponsor
- Augusta University
Scleroderma, Cardiac Involvement
Autologous Stem Cell Transplantation for Progressive Systemic Sclerosis
Autologous stem cell therapy has been shown to be effective in patients with systemic sclerosis. Nevertheless treatment is associated with treatment related mortality and patients die during follow up despite successful…
- Conditions
- Scleroderma, Cardiac Involvement, Autologous Stem Cell Transplantation
- Trial name
- AST-MOMA (NCT01895244)
- Testing
- Autologous stemcell transplantation with CD (cluster of differentiation) 34 selected stem cells
- Where
- Germany
- Volunteers
- 44 people
- Sponsor
- University Hospital Tuebingen
Autologous Stem Cell Transplantation, Allogeneic Stem Cell Transplantation
Protocol for a Research Sample Repository for Hematopoietic Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries
The primary purpose of the Research Sample Repository is to make blood samples available for research studies related to histocompatibility and hematopoietic cell transplantation (HCT) or other cellular therapy.
- Conditions
- Autologous Stem Cell Transplantation, Allogeneic Stem Cell Transplantation, Cellular Therapy, Marrow Toxic Injury
- Trial name
- NCT04920474
- Where
- United States
- Volunteers
- 99,999,999 people
- Sponsor
- Center for International Blood and Marrow Transplant Research
Autologous Stem Cell Transplantation, Conditioning
Modified BEAM Regimen for T Cell Lymphoma Underwent ASCT
A multicenter randomized study on the efficacy and safety of mitoxantrone hydrochloride liposome injection combined with carmustine, etoposide, and cytarabine (modified BEAM protocol) in the pretreatment of T-cell lymphoma…
- Trial name
- NCT05814718
- Testing
- modified BEAM, BEAM
- Where
- China
- Volunteers
- 122 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Lymphoma, Myeloma
Pedometer Activity Monitoring After ASCT
The trial assess the proportion of patients who resumed their professional activity within 100 days after ASCT (autologous stem cell Transplantation).
- Conditions
- Lymphoma, Myeloma, High-dose Chemotherapy, Autologous Stem Cell Transplantation
- Trial name
- PAMAL (NCT03238599)
- Testing
- Pedometer-based activity monitoring after ASCT
- Where
- Switzerland
- Volunteers
- 62 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Lymphoma, Autologous Hematopoietic Stem Cell Transplantation
Clinical Study of Improved BEAM Conditioning Regimen for ASCT in Lymphoma
This is a single arm, open, single-center clinical study. The patients who are diagnosed with lymphoma and intend to undergo ASCT will be enrolled.
- Trial name
- NCT05681403
- Testing
- Improved BEAM regimen
- Where
- China
- Volunteers
- 53 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Multiple Myeloma, Non-eligible for Autologous Stem Cell Transplantation (ASCT)
Evaluation of Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone Plus Daratumumab (VMP-Dara) in Newly Diagnosed Multiple Myeloma (MM) Patients Non-eligible for autoSCT
This is a prospective, observational, single group and multicenter study to describe the effectiveness and safety of maintenance with V-Dara after induction with the VMP-Dara regimen in newly diagnosed MM patients who are not…
- Trial name
- NCT05218603
- Testing
- Bortezomib, Daratumumab
- Where
- 32 sites in Spain
- Volunteers
- 100 people
- Sponsor
- PETHEMA Foundation
Hematopoietic Stem Cell Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation
Precision Dosing of Busulfan in Children Undergoing HSCT
The objective of this clinical trial is to evaluate the personalization the conditioning regimen prior to the hematopoietic stem cell transplant (HSCT) in children and adolescents, to improve HSCT efficacy while reducing…
- Conditions
- Hematopoietic Stem Cell Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation, Autologous Hematopoietic Stem Cell Transplantation
- Trial name
- BuGenes01 (NCT04822532)
- Testing
- GSTA1 genotyping
- Where
- Switzerland
- Volunteers
- 260 people
- Sponsor
- University Hospital, Geneva
Autologous Hematopoietic Stem Cell Transplantation, Acute Myeloid Leukemia
IDA+BUCY vs BUCY Conditioning Regimen for Intermediate-risk AML Undergoing Auto-HSCT
Autologous hematopoietic stem cell transplantation (Auto-HSCT) is an effective alternative to allogeneic HSCT for intermediate-risk acute myeloid leukemia (AML) without HLA-matched donors.
- Conditions
- Autologous Hematopoietic Stem Cell Transplantation, Acute Myeloid Leukemia, Conditioning
- Trial name
- NCT02671708
- Testing
- Idarubicin（IDA）, Busulfan (BU), Cyclophosphamide (CY)
- Where
- China
- Volunteers
- 153 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Autologous Hematopoietic Stem Cell Transplantation, Conditioning
Mel vs BUCY+VP-16 Conditioning Regimen for MM Undergoing Auto-HSCT
The purpose of this study is to evaluate the safety and efficacy of Melphalan and BUCY+VP-16 myeloablative conditioning regimens in multiple myeloma undergoing autologous hematopoietic stem cell transplantation.
- Conditions
- Autologous Hematopoietic Stem Cell Transplantation, Conditioning, Multiple Myeloma
- Trial name
- NCT03385096
- Testing
- Busulfan (BU), Cyclophosphamide (CY), Etoposide (VP-16)
- Where
- China
- Volunteers
- 122 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Primary Central Nervous System Lymphoma, Autologous Hematopoietic Stem Cell Transplantation
BUCYE Conditioning Regimen for PCNSL Undergoing Auto-HSCT
The purpose of this study is to evaluate the safety and efficacy of BUCYE conditioning regimens in primary central nervous system lymphoma undergoing autologous hematopoietic stem cell transplantation.
- Conditions
- Primary Central Nervous System Lymphoma, Autologous Hematopoietic Stem Cell Transplantation, Conditioning
- Trial name
- NCT03733327
- Testing
- Busulfan (BU), Cyclophosphamide (CY), Etoposide (VP-16)
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Nanfang Hospital, Southern Medical University